Bio-Path expects to utilize an advisory panel of AML experts to assist in the design of the final clinical development plans through potential FDA approval. Other significant milestones expected ...

US telehealth group explores selling ‘compounded medications’ in new markets after buying London-based rival Zava ...

The data shows that the average rate of adolescents starting treatment with the Novo Nordisk (NYSE: NVO) drug increased by 50 ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic ...

Women taking oral hormone replacement therapy are being advised to talk to their doctor if they also start using Mounjaro, ...

Patrick Gilligan, a former Blue Cross Blue Shield executive, will succeed Cain Hayes, who left the financially troubled ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Humans have spent thousands of years experimenting with weight loss aids. While Ozempic and Wegovy may be generating ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...